FDA renewal ensures federal committee oversees medical imaging drug safety until 2023

The U.S. Food and Drug Administration is renewing a charter to ensure the Medical Imaging Drugs Advisory Committee can continue recommending best practices for the field, the agency announced Thursday.

As part of the federal group, 12 voting members review and evaluate data concerning the safety and effectiveness of drugs for use in radiopharmaceuticals, contrast media and therapeutics intended for diagnostic radiology exams. The core members may include one individual with consumer interests and one non-voting member with similar ties.

The individuals serve overlapping terms of up to four years and make appropriate recommendations to the FDA Commissioner, currently Janet Woodcock, MD, who was named acting commissioner in January.

“The commissioner has determined that it is in the public interest to renew the Medical Imaging Drugs Advisory Committee for an additional two years beyond the charter expiration date,” the FDA said in its announcement.

This notice extends the committee’s authority until May 18, 2023.

Read the entire announcement here.

Around the web

The findings are part of a new Neiman Health Policy Institute analysis of National Mammography Database numbers from an 11-year period, highlighted in  RSNA's Radiology

MIT charts the encouraging story behind—and in front of—the National COVID Cohort Collaborative (N3C ).

The academic imaging department found that plain computed tomography head scans produced numerous phone calls from referrers, pulling rads away from their work. 

American Orthopedic Partners CEO Jay Bronner, MD, is joined by fellow RP alum Ryan Pahler, the imaging giant's former VP of national business development.